10-Q Filing

SWK Holdings Corp CIK: 1089907 Q2 2022

Filing Information

Form Type	10-Q
Accession Number	`0001552781-22-000529`
Period End Date	20220630
Filing Date	20220810
Fiscal Year	2022
Fiscal Period	Q2
XBRL Instance	e22387_swkh-10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 76 Income Statement 76 Cash Flow Statement 64 Stockholders Equity 26

Balance Sheet 76 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, Par or Stated Value Per Share	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, Par or Stated Value Per Share	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, Shares Authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred Stock, Shares Authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.62M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$55.12M	USD	Point-in-time
Preferred Stock, Shares Issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$42.86M	USD	Point-in-time
Preferred Stock, Shares Issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Interest and accounts receivable, net	`AccountsReceivableNet`	$1.87M	USD	Point-in-time
Interest and accounts receivable, net	`AccountsReceivableNet`	$1.80M	USD	Point-in-time
Preferred Stock, Shares Outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred Stock, Shares Outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Marketable investments	`MarketableSecurities`	$487.00K	USD	Point-in-time
Marketable investments	`MarketableSecurities`	$1.03M	USD	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.73M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.37M	USD	Point-in-time
Common Stock, Shares, Issued	`CommonStockSharesIssued`	12.84M	shares	Point-in-time
Common Stock, Shares, Issued	`CommonStockSharesIssued`	12.84M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$58.84M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$47.43M	USD	Point-in-time
Finance receivables, net	`NotesAndLoansReceivableNetCurrent`	$174.86M	USD	Point-in-time
Common Stock, Shares, Outstanding	`CommonStockSharesOutstanding`	12.84M	shares	Point-in-time
Common Stock, Shares, Outstanding	`CommonStockSharesOutstanding`	12.84M	shares	Point-in-time
Finance receivables, net	`NotesAndLoansReceivableNetCurrent`	$181.55M	USD	Point-in-time
Marketable investments	`AvailableForSaleSecuritiesDebtSecurities`	$98.00K	USD	Point-in-time
Marketable investments	`AvailableForSaleSecuritiesDebtSecurities`	$119.00K	USD	Point-in-time
Cost method investment	`CostMethodInvestments`	$3.49M	USD	Point-in-time
Cost method investment	`CostMethodInvestments`	$3.49M	USD	Point-in-time
Deferred tax assets, net	`DeferredIncomeTaxAssetsNet`	$19.28M	USD	Point-in-time
Deferred tax assets, net	`DeferredIncomeTaxAssetsNet`	$20.54M	USD	Point-in-time
Warrant assets	`WarrantAssets`	$2.48M	USD	Point-in-time
Warrant assets	`WarrantAssets`	$3.42M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$9.04M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$9.96M	USD	Point-in-time
Goodwill	`Goodwill`	$8.40M	USD	Point-in-time
Goodwill	`Goodwill`	$8.40M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$6.07M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$5.78M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$1.97M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$1.86M	USD	Point-in-time
Total assets	`Assets`	$282.67M	USD	Point-in-time
Total assets	`Assets`	$284.43M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.78M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$5.09M	USD	Point-in-time
Revolving credit facility	`LinesOfCreditCurrent`	$8.00K	USD	Point-in-time
Revolving credit facility	`LinesOfCreditCurrent`	-	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.78M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$5.09M	USD	Point-in-time
Contingent consideration payable	`ContingentConsiderationPayable`	$8.53M	USD	Point-in-time
Contingent consideration payable	`ContingentConsiderationPayable`	$8.53M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$1.80M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$1.59M	USD	Point-in-time
Total liabilities	`Liabilities`	$12.89M	USD	Point-in-time
Total liabilities	`Liabilities`	$15.43M	USD	Point-in-time
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,839,118 and 12,836,133 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	`CommonStockValue`	$13.00K	USD	Point-in-time
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,839,118 and 12,836,133 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	`CommonStockValue`	$13.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.43B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.43B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-4.16B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-4.16B	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$267.24M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$240.51M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$258.24M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$270.80M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$271.53M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$244.08M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$284.43M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$282.67M	USD	Point-in-time

Income Statement 76 line items

Line Item	Tag	Value	Unit	Period
Finance receivable interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$17.24M	USD	2 Qtrs
Finance receivable interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$6.83M	USD	1 Quarter
Finance receivable interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$20.48M	USD	2 Qtrs
Finance receivable interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$11.80M	USD	1 Quarter
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$114.00K	USD	1 Quarter
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$10.66M	USD	2 Qtrs
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$350.00K	USD	2 Qtrs
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$10.46M	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomerOther`	-	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomerOther`	$496.00K	USD	2 Qtrs
Other	`RevenueNotFromContractWithCustomerOther`	-	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomerOther`	$480.00K	USD	2 Qtrs
Total revenues	`Revenues`	$18.07M	USD	2 Qtrs
Total revenues	`Revenues`	$6.94M	USD	1 Quarter
Total revenues	`Revenues`	$31.64M	USD	2 Qtrs
Total revenues	`Revenues`	$22.27M	USD	1 Quarter
Interest expense	`InterestExpense`	$239.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$160.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$94.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$80.00K	USD	1 Quarter
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$3.09M	USD	2 Qtrs
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$1.48M	USD	1 Quarter
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$1.54M	USD	1 Quarter
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$3.38M	USD	2 Qtrs
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	-	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$-147.00K	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	-	USD	2 Qtrs
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$-147.00K	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationAndAmortization`	$626.00K	USD	1 Quarter
Depreciation and amortization expense	`DepreciationAndAmortization`	$1.33M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationAndAmortization`	$2.49M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationAndAmortization`	$811.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$6.25M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$3.36M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.02M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$6.18M	USD	2 Qtrs
Income from operations	`OperatingIncomeLoss`	$1.74M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$16.61M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$7.02M	USD	2 Qtrs
Income from operations	`OperatingIncomeLoss`	$19.72M	USD	2 Qtrs
Unrealized net (loss) gain on derivatives	`UnrealizedGainLossOnDerivatives`	$-1.17M	USD	2 Qtrs
Unrealized net (loss) gain on derivatives	`UnrealizedGainLossOnDerivatives`	$-472.00K	USD	1 Quarter
Unrealized net (loss) gain on derivatives	`UnrealizedGainLossOnDerivatives`	$609.00K	USD	1 Quarter
Unrealized net (loss) gain on derivatives	`UnrealizedGainLossOnDerivatives`	$892.00K	USD	2 Qtrs
Unrealized net (loss) gain on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-519.00K	USD	1 Quarter
Unrealized net (loss) gain on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$283.00K	USD	1 Quarter
Unrealized net (loss) gain on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$1.22M	USD	2 Qtrs
Unrealized net (loss) gain on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-547.00K	USD	2 Qtrs
Income before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$17.50M	USD	1 Quarter
Income before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$21.83M	USD	2 Qtrs
Income before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$747.00K	USD	1 Quarter
Income before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$5.31M	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$1.27M	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$182.00K	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$4.47M	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$3.53M	USD	1 Quarter
Net income	`ProfitLoss`	$13.97M	USD	1 Quarter
Net income	`ProfitLoss`	$17.36M	USD	2 Qtrs
Net income	`ProfitLoss`	$565.00K	USD	1 Quarter
Net income	`ProfitLoss`	$4.04M	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$0.04	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.32	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$1.36	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$1.09	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.04	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.31	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$1.09	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$1.35	USD	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	12.84M	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	12.79M	shares	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	12.83M	shares	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	12.80M	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.88M	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.82M	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.88M	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.83M	shares	1 Quarter

Cash Flow Statement 64 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$13.97M	USD	1 Quarter
Net income	`ProfitLoss`	$17.36M	USD	2 Qtrs
Net income	`ProfitLoss`	$565.00K	USD	1 Quarter
Net income	`ProfitLoss`	$4.04M	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$93.00K	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$29.00K	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$1.26M	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$4.37M	USD	2 Qtrs
Change in fair value of warrants	`FairValueAdjustmentOfWarrants`	$1.17M	USD	2 Qtrs
Change in fair value of warrants	`FairValueAdjustmentOfWarrants`	$-892.00K	USD	2 Qtrs
Change in fair value of equity securities	`IncreaseDecreaseInEquitySecuritiesFvNi`	$-547.00K	USD	2 Qtrs
Change in fair value of equity securities	`IncreaseDecreaseInEquitySecuritiesFvNi`	$1.22M	USD	2 Qtrs
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	-	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$-147.00K	USD	1 Quarter
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	-	USD	2 Qtrs
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$-147.00K	USD	2 Qtrs
Loan discount amortization and fee accretion	`AmortizationOfDeferredLoanOriginationFeesNet`	$780.00K	USD	2 Qtrs
Loan discount amortization and fee accretion	`AmortizationOfDeferredLoanOriginationFeesNet`	$1.13M	USD	2 Qtrs
Interest income paid-in-kind	`PaidInKindInterest`	$26.00K	USD	2 Qtrs
Interest income paid-in-kind	`PaidInKindInterest`	$1.60M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$364.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$187.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$85.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$251.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$177.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$166.00K	USD	1 Quarter
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$2.49M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$1.33M	USD	2 Qtrs
Interest and accounts receivable	`IncreaseDecreaseInInterestAndDividendsReceivable`	$-66.00K	USD	2 Qtrs
Interest and accounts receivable	`IncreaseDecreaseInInterestAndDividendsReceivable`	$-728.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$256.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$477.00K	USD	2 Qtrs
Accounts payable and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-813.00K	USD	2 Qtrs
Accounts payable and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-2.53M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$3.40M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$19.25M	USD	2 Qtrs
Investment in finance receivables	`PaymentsToAcquireFinanceReceivables`	$25.35M	USD	2 Qtrs
Investment in finance receivables	`PaymentsToAcquireFinanceReceivables`	$20.10M	USD	2 Qtrs
Repayment of finance receivables	`ProceedsRepaymentOfFinanceReceivables`	$34.20M	USD	2 Qtrs
Repayment of finance receivables	`ProceedsRepaymentOfFinanceReceivables`	$22.78M	USD	2 Qtrs
Corporate debt securities principal payments	`MarketableInvestmentPrincipalPayment`	$31.00K	USD	2 Qtrs
Corporate debt securities principal payments	`MarketableInvestmentPrincipalPayment`	$21.00K	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$671.00K	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$111.00K	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-113.00K	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-163.00K	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$2.20M	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$8.87M	USD	2 Qtrs
Net payments on credit facility	`ProceedsFromRepaymentsOfLinesOfCredit`	$-8.00K	USD	2 Qtrs
Net payments on credit facility	`ProceedsFromRepaymentsOfLinesOfCredit`	$-11.76M	USD	2 Qtrs
Payment of acquisition-related contingent consideration	`PaymentForContingentConsiderationLiabilityFinancingActivities`	-	USD	2 Qtrs
Payment of acquisition-related contingent consideration	`PaymentForContingentConsiderationLiabilityFinancingActivities`	$6.08M	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-8.00K	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-17.84M	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$3.61M	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$12.26M	USD	2 Qtrs
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$6.62M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$55.12M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$3.01M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$42.86M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$6.62M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$55.12M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$3.01M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$42.86M	USD	Point-in-time

Stockholders Equity 26 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$267.24M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$240.51M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$258.24M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$270.80M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$271.53M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$244.08M	USD	Point-in-time
Stock-based compensation	`ShareBasedCompensation`	$364.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$187.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$85.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$251.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$177.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$166.00K	USD	1 Quarter
Issuance of common stock upon vesting of restricted stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of common stock upon vesting of restricted stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of common stock upon vesting of restricted stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of common stock upon vesting of restricted stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Net income	`NetIncomeLoss`	$565.00K	USD	1 Quarter
Net income	`NetIncomeLoss`	$13.97M	USD	1 Quarter
Net income	`NetIncomeLoss`	$3.39M	USD	1 Quarter
Net income	`NetIncomeLoss`	$3.48M	USD	1 Quarter
Ending balance, value	`StockholdersEquity`	$267.24M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$240.51M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$258.24M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$270.80M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$271.53M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$244.08M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.